Shenkang injection (SKI) is a classic prescription composed of Radix Astragali, rhubarb, Astragalus, Safflower, and Salvia. This treatment was approved by the State Food and Drug Administration of China in 1999 for treatment of chronic kidney diseases based on good efficacy and safety. This study aimed to investigate the protective effect of SKI against high glucose (HG)-induced renal tubular cell senescence and its underlying mechanism. Primary renal proximal tubule epithelial cells were cultured in (1) control medium (control group), medium containing 5 mmol/L glucose; (2) mannitol medium (mannitol group), medium containing 5 mmol/L glucose, and 25 mmol/L mannitol; (3) HG medium (HG group) containing 30 mmol/L glucose; (4) SKI treatment at high (200 mg/L), medium (100 mg/L), or low (50 mg/L) concentration in HG medium (HG+ SKI group); or (5) 200 mg/L SKI treatment in control medium (control+ SKI group) for 72 h. HG-induced senescent cells showed the emergence of senescence associated heterochromatin foci, up-regulation of P16INK4 and cyclin D1, increased senescence-associated β-galactosidase activity, and elevated expression of membrane decoy receptor 2. SKI treatment potently prevented these changes in a dose-independent manner. SKI treatment prevented HG-induced up-regulation of pro-senescence molecule mammalian target of rapamycin and p66Shc and down-regulation of anti-senescence molecules klotho, sirt1, and peroxisome proliferator-activated receptor-g in renal tubular epithelial cells. SKI may be a novel strategy for protecting against HG-induced renal tubular cell senescence in treatment of diabetic nephropathy.
SMenini, L Amadio, GOddi, CRicci, CPesce, FPugliese, MGiorgio, EMigliaccio, PPelicci, CIacobini, GPugliese. Deletion of p66Shc longevity gene protects against experimental diabetic glomerulopathy by preventing diabetes-induced oxidative stress. Diabetes 2006; 55(6): 1642–1650 https://doi.org/10.2337/db05-1477
pmid: 16731826
8
ZQNing. Qiao Y, Bai J, Wang JW, Huang XF, Zhao X, Xu HC, Wen AD. Treatment of early diabetic nephropathy with Shenkang injection: a meta-analysis. J Shanxi College Trad Chin Med (Shanxi Zhong Yi Xue Yuan Xue Bao) 2014; 37: 39–43 (in Chinese)
9
ZWJiang, YY Lu, JLXia. The phase IV clinical observation study of Shenkang injection on chronic renal failure. J China Med Univ (Zhongguo Yi Ke Da Xue Xue Bao ) 2011; 40(10): 941–945 (in Chinese)
10
ZYong, R Yang, JChen. Shenkang injection in the treatment of diabetic nephropathy meta-analysis. J Liaoning Univ Trad Chin Med (Liaoning Zhong Yi Yao Da Xue Xue Bao) 2015; 17: 165–167 (in Chinese)
11
XWu, Y Guan, JYan, MLiu, Y Yin, JDuan, GWei, T Hu, YWeng, MXi, A Wen. Shenkang injection suppresses kidney fibrosis and oxidative stress via transforming growth factor-β/Smad3 signalling pathway in vivo and in vitro. J Pharm Pharmacol 2015; 67(8): 1054–1065 https://doi.org/10.1111/jphp.12412
pmid: 25864844
12
Chen HDu J,, XWang. Song L, He YH, Ye CH. Effect of Shengkang injection on hypertrophy and expression of p21 and p27 in glomerular mesangial cells of rats cultured in high glucose. Chin J Integr Trad West Med (Zhongguo Zhong Xi Yi Jie He Za Zhi ) 2006; 26: 68–71 (in Chinese)
13
SYao, J Zhang, DWang, JHou, W Yang, JDa, LCai, M Yang, BJiang, XLiu, D Guo, WWu. Discriminatory components retracing strategy for monitoring the preparation procedure of Chinese patent medicines by fingerprint and chemometric analysis. PLoS One 2015; 10(3):e0121366
14
STerryn, F Jouret, FVandenabeele, ISmolders, MMoreels, ODevuyst, PSteels, EVan Kerkhove. A primary culture of mouse proximal tubular cells, established on collagen-coated membranes. Am J Physiol Renal Physiol 2007; 293(2): F476–F485 https://doi.org/10.1152/ajprenal.00363.2006
pmid: 17475898
15
ACBreggia, J Himmelfarb. Primary mouse renal tubular epithelial cells have variable injury tolerance to ischemic and chemical mediators of oxidative stress. Oxid Med Cell Longev 2008; 1(1): 33–38
16
SKroening, E Neubauer, BWullich, JAten, M Goppelt-Struebe. Characterization of connective tissue growth factor expression in primary cultures of human tubular epithelial cells: modulation by hypoxia. Am J Physiol Renal Physiol 2010; 298(3): F796–F806 https://doi.org/10.1152/ajprenal.00528.2009
pmid: 20032117
17
JSatriano, H Mansoury, ADeng, KSharma, VVallon, RCBlantz, SCThomson. Transition of kidney tubule cells to a senescent phenotype in early experimental diabetes. Am J Physiol Cell Physiol 2010; 299(2): C374–C380 https://doi.org/10.1152/ajpcell.00096.2010
pmid: 20505038
18
JFNavarro-González, CMora-Fernández, MMuros de Fuentes, JGarcía-Pérez. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011; 7(6): 327–340 https://doi.org/10.1038/nrneph.2011.51
pmid: 21537349
19
HBraun, BMW Schmidt, MRaiss, ABaisantry, DMircea-Constantin, SWang, ML Gross, MSerrano, RSchmitt, AMelk. Cellular senescence limits regenerative capacity and allograft survival. J Am Soc Nephrol 2012; 23(9): 1467–1473 https://doi.org/10.1681/ASN.2011100967
pmid: 22797186
TTchkonia, Y Zhu, Jvan Deursen, JCampisi, JLKirkland. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest 2013; 123(3): 966–972 https://doi.org/10.1172/JCI64098
pmid: 23454759
23
YUZhang, N Zhou, HWang, SWang, J He. Effect of Shenkang granules on the progression of chronic renal failure in 5/6 nephrectomized rats. Exp Ther Med 2015; 9(6): 2034–2042 https://doi.org/10.3892/etm.2015.2383
pmid: 26136932
24
BMolgora, R Bateman, GSweeney, DFinger, TDimler, RBEffros, HFValenzuela. Functional assessment of pharmacological telomerase activators in human T cells. Cells 2013; 2(1): 57–66 https://doi.org/10.3390/cells2010057
pmid: 24709644
25
GHu, J Liu, YZZhen, RXu, Y Qiao, JWei, PTu, YJ Lin. Rhein lysinate increases the median survival time of SAMP10 mice: protective role in the kidney. Acta Pharmacol Sin 2013; 34(4): 515–521 https://doi.org/10.1038/aps.2012.177
pmid: 23474705
26
GGCamici, M Schiavoni, PFrancia, MBachschmid, IMartin-Padura, MHersberger, FCTanner, PPelicci, MVolpe, PAnversa, TFLüscher, FCosentino. Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. Proc Natl Acad Sci USA 2007; 104(12): 5217–5222 https://doi.org/10.1073/pnas.0609656104
pmid: 17360381
MKitada, S Kume, ATakeda-Watanabe, KKanasaki, DKoya. Sirtuins and renal diseases: relationship with aging and diabetic nephropathy. Clin Sci (Lond) 2013; 124(3): 153–164 https://doi.org/10.1042/CS20120190
pmid: 23075334
29
OAsai, K Nakatani, TTanaka, HSakan, AImura, SYoshimoto, KSamejima, YYamaguchi, MMatsui, YAkai, N Konishi, MIwano, YNabeshima, YSaito. Decreased renal α-Klotho expression in early diabetic nephropathy in humans and mice and its possible role in urinary calcium excretion. Kidney Int 2012; 81(6): 539–547 https://doi.org/10.1038/ki.2011.423
pmid: 22217880
30
HCYang, S Deleuze, YZuo, SAPotthoff, LJMa, AB Fogo. The PPARγ agonist pioglitazone ameliorates aging-related progressive renal injury. J Am Soc Nephrol 2009; 20(11): 2380–2388 https://doi.org/10.1681/ASN.2008111138
pmid: 19797472
31
YLin, M Kuro-o, ZSun. Genetic deficiency of anti-aging gene klotho exacerbates early nephropathy in STZ-induced diabetes in male mice. Endocrinology 2013; 154(10): 3855–3863 https://doi.org/10.1210/en.2013-1053
pmid: 23928372
32
SXu, Y Cai, YWei. mTOR signaling from cellular senescence to organismal aging. Aging Dis 2013; 5(4): 263–273
pmid: 25110610
33
SKume, M Kitada, KKanasaki, HMaegawa, DKoya. Anti-aging molecule, Sirt1: a novel therapeutic target for diabetic nephropathy. Arch Pharm Res 2013; 36(2): 230–236 https://doi.org/10.1007/s12272-013-0019-4
pmid: 23361587
34
WHe, Y Wang, MZZhang, LYou, LS Davis, HFan, HCYang, ABFogo, RZent, RC Harris, MDBreyer, CMHao. Sirt1 activation protects the mouse renal medulla from oxidative injury. J Clin Invest 2010; 120(4): 1056–1068 https://doi.org/10.1172/JCI41563
pmid: 20335659
35
MKKim, SW Chung, DHKim, JMKim, EK Lee, JYKim, YMHa, YH Kim, JKNo, HSChung, KYPark, SHRhee, JSChoi, BPYu, T Yokozawa, YJKim, HYChung. Modulation of age-related NF-κB activation by dietary zingerone via MAPK pathway. Exp Gerontol 2010; 45(6): 419–426 https://doi.org/10.1016/j.exger.2010.03.005
pmid: 20211236
36
TYamagishi, Y Saito, TNakamura, STakeda, HKanai, HSumino, MKuro-o, YNabeshima, MKurabayashi, RNagai. Troglitazone improves endothelial function and augments renal klotho mRNA expression in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with multiple atherogenic risk factors. Hypertens Res 2001; 24(6): 705–709 https://doi.org/10.1291/hypres.24.705
pmid: 11768731
37
HZhang, Y Li, YFan, JWu, B Zhao, YGuan, SChien, NWang. Klotho is a target gene of PPAR-γ. Kidney Int 2008; 74(6): 732–739 https://doi.org/10.1038/ki.2008.244
pmid: 18547997
38
MMSpeeckaert, C Vanfraechem, RSpeeckaert, JRDelanghe. Peroxisome proliferator-activated receptor agonists in a battle against the aging kidney. Ageing Res Rev 2014; 14: 1–18 https://doi.org/10.1016/j.arr.2014.01.006
pmid: 24503003
39
MVBlagosklonny. TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists. Cell Death Dis 2013; 4(12): e964 https://doi.org/10.1038/cddis.2013.506
pmid: 24336084